Material Transfer and Evaluation Agreement: Testing the immune response to SARS-CoV-2 Spike subunit vaccine

Vaxxas is planning to test a SARS-CoV-2 Spike subunit vaccine called Hexapro in a Phase I clinical trial later this year. As a prerequisite to this trial, a rat toxicology study was performed and one of the rats (out of 20 tested in the vaccine arm) had developed enhanced cellular infiltration into the bone marrow and potentially into the spleen at necropsy. Vaxxas plans to investigate why this could be the case because the infiltration was perceived as 'unusual'. Given that this single rat had the highest IgG ELISA response amongst all of the rats tested, Vaxxas could like to understand if this rat had generated an exaggerated immune response.